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ABSTRACT:
Dapagliflozin (2S,3R,4R,5S,6R)-2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyl-tetrahydro-2H-pyran-3,4,5-triol; BMS-512148) is a potent sodiumglucose cotransporter type II inhibitor in animals and humans and is currently under development for the treatment of type 2 diabetes. The preclinical characterization of dapagliflozin, to allow compound selection and prediction of pharmacological and dispositional behavior in the clinic, involved Caco-2 cell permeability studies, CYP inhibition and induction studies, CYP reaction phenotyping, metabolite identification in hepatocytes and pharmacokinetics in rats, dogs, and monkeys. Dapagliflozin was found to have good permeability across Caco-2 cell membranes. It was found to be a substrate for P-glycoprotein (P-gp)
but not a significant P-gp inhibitor. Dapagliflozin was not found to be an inhibitor or an inducer of human CYP enzymes. The in vitro metabolic profiles of dapagliflozin after incubation with hepatocytes from mice, rats, dogs, monkeys, and humans were qualitatively similar. Rat hepatocyte incubations showed the highest turnover and dapagliflozin was most stable in human hepatocytes. Prominent in vitro metabolic pathways observed were glucuronidation, hydroxylation, and Odeethylation. Pharmacokinetic parameters for dapagliflozin in preclinical species revealed a compound with adequate oral exposure, clearance, and elimination half-life, consistent with the potential for single daily dosing in humans. Indeed, the pharmacokinetics in humans after a single dose of 50 mg of [ 14 C]dapagliflozin showed good exposure, low clearance, adequate half-life, and no metabolites with significant pharmacological activity or toxicological concern.
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Introduction
Type 2 diabetes mellitus is a chronic disease prevalent around the world, characterized by hyperglycemia due to excessive hepatic glucose production, a deficiency in insulin secretion and/or peripheral insulin resistance. As the disease advances, complications result from the hyperglycemia, such as retinopathy, neuropathy, nephropathy and other macrovascular diseases (Porte, 2001; Edelman, 1998) . While present antidiabetic agents can achieve the needed reduction in plasma glucose, no single current medication is optimal to achieve sustained glycemic control without side effects, such as hypoglycemia.
And the often necessary combination therapy can generate additional side effects. For example, treatment with thiazolidinediones (glitazones) in combination with insulin are related to an increased risk of congestive heart failure due to edema events (Nesto et al., 2004) . There are very few therapies, with the exception of the novel dipeptidyl peptidase 4 (DPP-4) inhibition, that do not cause an increase in body weight or risk of hypoglycemia (Barnett, 2006) . In addition, agents that increase the production of insulin stress the pancreatic beta cells, which results in eventual hypertrophy and loss of differentiation of those cells, contributing to the progression of the disease (List, et.al., 2008) .
Thus, the development of alternative agents acting by novel mechanisms has become necessary in order to control glucose levels in patients with progressing hyperglycemia (Rotella, 2004; Skyler, 2004; Mohler et al., 2008; ) . Some emerging small molecules primarily lower blood glucose levels by modulating targets that affect glucose metabolism (glucokinase, glycogen phosphorylase) or by regulating glucose homeostasis (AMP activated protein kinase). One such novel mechanism by which blood glucose levels can be DMD 29165
-6 -lowered is by removing glucose from the bloodstream via inhibition of the sodium glucose co-transporter SGLT.
Under normal conditions, plasma glucose is filtered in the kidney glomerulus and in healthy individuals is almost totally (99%) reabsorbed (Deetjen et al., 1992) . This reabsorption process is mediated by two sodium-dependent glucose cotransporters-SGLT1
and SGLT2. SGLT1 is a low capacity, high-affinity transporter expressed in the gut, heart, and kidney (Wright et al., 1993) , and SGLT2 is a high-capacity, low-affinity transporter expressed mainly in the S1 segment of the proximal tubule of the nephron (Kanai, et al., 1994) . The SGLT2 in the proximal tubule is estimated to facilitate about 90% of renal glucose reabsorption, and the remaining 10% is likely mediated by SGLT1 that resides in the distal S3 segment of the proximal tubule (Wallner, et al., 2001 ).
Nonselective SGLT inhibitors have been described, such as the natural product phlorizin (Ehrenkranz et al., 2005) , which is an O-glucoside dihydrochalcone found in the root and bark of certain fruit trees. Phlorizin was not suitable for development as a drug candidate due to low bioavailability and rapid clearance as a consequence of hydrolysis by Oglucosidases present in the gut, liver and kidney. In addition, the finding that a defective SGLT1 transporter in the gut is responsible for glucose and galactose malabsorption disorders in patients (Turk et al., 1991) suggests that pursuit of SGLT2 inhibitors exhibiting comparable (less than tenfold) SGLT1 selectivity to phlorizin would increase the risk of unacceptable diarrhea.
Selective inhibition of SGLT2 has been proposed to aid in the normalization of plasma glucose levels in diabetics by preventing the renal glucose reabsorption process and promoting glucose excretion in urine (Oku et al., 1999) . Dapagliflozin is a potent, selective DMD 29165
-7 -SGLT2 inhibitor in vitro, and also demonstrates increased glucose excretion and highly efficacious plasma glucose lowering in preclinical species Meng et al., 2008) . Dapagliflozin is not only selective for SGLT2 (1200-fold over SGLT1) but is also more metabolically stable than previously described SGLT inhibitors since it is a Cglucoside rather than an O-glucoside Meng et al, 2008) . Proof of concept and phase 2b studies in patients with type 2 diabetes have been conducted with various doses of dapagliflozin and published previously (List et al., 2008; ; ). Dapaglifozin exhibits an insulin-independent mechanism of action, providing both short term and longer term (HbA1c levels) efficacy (List et al., 2008) . In studies with the SGLT inhibitor phlorizin, this insulin-independent mechanism was shown to alleviate the loss of beta cell function, normalizing the blood glucose levels without increasing plasma insulin or changing levels of nonesterified fatty acids in plasma (Jonas et al., 1999) .
Once C-glycoside SGLT2 inhibitors were identified as being pharmacologically attractive compounds, with very good selectivity for the target, and potency in both in vitro and in vivo assessments, studies were conducted to characterize the in vitro absorption, metabolism, drug-drug interaction potential, and pharmacokinetics in mice, rats, dogs, and monkeys, to aid in compound selection. Based on the data from these evaluations, dapagliflozin was selected for progression into clinical trials and the ADME-related data is presented in this manuscript. As dapagliflozin progressed as the development candidate, a mass balance study with radiolabeled dapaglifozin was conducted in healthy volunteers, and some brief results from that study are also reported here. Those that received the intravenous doses had chronically implanted femoral vein access ports. Adult male cynomolgus monkeys (6.2-7.1 kg) were from an in-house colony. All the monkeys used had chronically implanted femoral vein access ports. All animals were fasted overnight prior to dosing and were fed 4 h after dosing. All animals had free access to water and were conscious throughout the study.
Drug.
For all pharmacokinetic studies in animals, dapagliflozin was formulated in polyethylene glycol (PEG 400): water: ethanol (45:45:10, v:v:v) at a concentration of 1 mg/mL.
Drug Treatment. Two groups of three rats each were given a single oral or intraarterial dose of dapagliflozin (1 mg/kg). A single dose of dapagliflozin (6.6 mg/kg) was administered orally and intravenously to three beagle dogs in a crossover fashion. In an analogous crossover study, dapagliflozin (6 mg/kg) was administered orally and intravenously to three cynomolgus monkeys.
Sampling. For rats, blood samples were collected from the jugular vein cannulae, at 10 and 30 min, and 1, 2, 4, 6, 8, and 12 h after both the intraarterial and oral administration. 25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, and 312 The permeability studies were conducted as described previously (Kamath et al., 2008) , but with the addition of a potent inhibitor of P-gp (GF-120918, 4 μM), to both the apical and the basolateral compartments in the bi-directional permeability studies. The ability of dapagliflozin to inhibit P-gp was evaluated by assessing the inhibition of the transport of digoxin, a P-gp substrate, through Caco-2 cell monolayers, and was conducted as described previously (Kamath et al., 2008) .
Plasma protein binding. The protein binding of dapagliflozin in rat, dog, and human plasma was determined in a 96-well equilibrium dialysis apparatus using dialysis membranes with a 12,000-to 14,000-dalton molecular weight cutoff (HTDialysis, LLC, Gales Ferry, CT). The dialysis buffer was 0.133 M sodium phosphate buffer (pH 7.4).
Plasma (previously frozen) was spiked with dapagliflozin (1 mM in ACN) to achieve final concentrations of 10 μM. The dialysis was conducted in triplicate for 4 h at 37°C.
Aliquots of plasma dialysates were analyzed using an LC/MS/MS method. The unbound fraction (f u ) was calculated as the concentration of dapagliflozin in the plasma dialysate Lot No. 27, pooled from 38 individuals; 0.05~0.25 mg/mL microsomal protein) were incubated in triplicate as described previously (Yao et al., 2007) .
CYP induction studies in hepatocytes and sample analysis. Primary cultures of human
hepatocytes were prepared at CellzDirect from human liver tissue from three donors (Hu472, Hu476, and Hu477). The CYP induction studies were conducted by CellzDirect (Pittsboro, NC), and a brief description of the study is shown below. A fresh stock solution of dapagliflozin was prepared in DMSO on the first day of dosing. Stock solutions were diluted daily in modified Chee's medium to achieve the final dosing concentrations of 0.2, 2 and 20 μ M for dapagliflozin and a final DMSO concentration of 0.1%. Primary human hepatocytes were prepared from human liver tissue from three donors. Hepatocytes were isolated by a collagenase perfusion method previously described (LeCluyse et al., 2005) .
Final cell viability prior to plating was determined by the Trypan Blue exclusion test and was greater than 75% in all cases.
Hepatocyte cultures were treated for three consecutive days with media containing dapagliflozin (0.2, 2 and 20 μ M), solvent (0.1% DMSO) controls or prototypical inducers.
Rifampicin (RIF, 10 μ M), phenobarbital (PB, 1 mM) and 3-methylcholanthrene (3-MC, 2 μ M) were the prototypical inducers used as positive controls for the human hepatocyte were stored at -70°C. Microsomes were diluted in 100 mM potassium phosphate buffer at pH 7.4, spiked with marker substrate and were equilibrated to 37°C. Total incubation volumes were approximately 0.5 mL and all incubations were performed in triplicate.
Metabolic reactions were initiated by the addition of NADPH (1 mM final concentration) and stopped at the indicated time points by addition of organic solvent. Samples were then extracted and analyzed for acetaminophen, hydroxybupropion, and 6β-hydroxytestosterone.
Following a 48 h incubation, cells from each treatment group were washed with HBSS, lysed with RLT buffer (Qiagen, Valencia, CA) and 1% β-mercaptoethanol, harvested, and
This article has not been copyedited and formatted. The final version may differ from this version. evaporated to dryness with a rotavapor, and the residue was dissolved in 3 mL of DMSO.
After removal of insoluble material by centrifugation (12,000xg for 3 min), the DMSO solution was subjected to semipreparative HPLC separation.
Analysis. Samples from the Caco-2 permeability studies were analyzed on an HPLC system that consisted of the 2690 Waters separation module and a Waters 996 photodiode array detector (Waters, Milford, MA). The column used was YMC ODS-AQ 4.6 mm X 150 mm, 3 micron particle, maintained at 25°C and a flow rate of 1 mL/min. Caco-2 samples (100 μL) were injected without any sample preparation. An ACN:water gradient system was used for the separation. The amount of ACN in the gradient was increased in a stepwise fashion from 5% ACN to 90% ACN over 6 min, held for 7 min, then reequilibrated to 5% ACN over 5 min. The mobile phases also contained 0.115% trifluoroacetic acid. Quantitation was based on the UV peak area of dapagliflozin (at 210 nm) in the samples.
Analysis of the metabolites from the probe substrates used in the microsomal incubations was conducted using assays that were developed and validated at Bristol-Myers Squibb Co. (Yao et al., 2007) . Quantitation of the metabolites from the three probe substrates used in the CYP induction studies were conducted as described previously (LeCluyse et al., 2005) .
The analysis of metabolite profiles in hepatocytes was conducted on an HPLC system that consisted of two Shimadzu LC10AD pumps, a model SCL system controller, a model SIL 10 AD autoinjector, and a model SPD M10A diode-array detector (Shimadzu, Columbia, MD). The column used was Zorbax C18 (4.6 x 250 mm, 5 μm) column, run at ambient temperature and a flow rate of 0.8 mL/min. Hepatocyte samples were treated with two This article has not been copyedited and formatted. The final version may differ from this version. (Waters, Milford, MA) and a flow rate of 10 mL/min was used. An ACN:water gradient system was used for the separation. The amount of ACN in the gradient was increased in a stepwise fashion starting with 10% ACN held for 5 min, then to 32% ACN over 2 min, held at 32% ACN for 13 min, then re-equilibrated to 10% ACN. M12 eluted around 17 min in this system. Fractions containing M12 were pooled and lyophilized. Plasma samples at 1, 4, and 12 h were profiled for metabolites using the same HPLC procedure as for the hepatocyte incubations (the total radioactivity measurements were BQL after 24 h, so the 48 and 144 h samples were not profiled). The plasma samples were loaded into the extraction wells, followed by 400 μL of water, then 2 x 400 μL of 10% methanol in water. Samples were eluted with 2 x 400 μL of methanol. The eluted fractions were evaporated to dryness under nitrogen and reconstituted in 400 μL of methanol/water (25:75, v/v). Following centrifugation, a 100 μL portion was analyzed by HPLC for biotransformation profiling and mass spectral analysis. Radioactivity at the retention time correlating to the glucuronide conjugate of dapagliflozin M15 was also quantified and converted to concentration using a specific activity of 2.07 μCi/mg. Total radioactivity was determined in these plasma samples by liquid scintillation counting (LSC).
This article has not been copyedited and formatted. The final version may differ from this version. Pharmacokinetic data analysis. All plasma concentration vs. time data of dapagliflozin were analyzed by noncompartmental methods (Gibaldi, 1982) (Davies and Morris, 1993) . Vss values were compared to total body water reported for the various species (Davies and Morris, 1993) . The absolute oral bioavailability (expressed as %) was estimated by comparing the ratio of dose-normalized AUC values after oral doses to those after intravenous doses. To obtain the percent of dose excreted in urine, the amount of dapagliflozin excreted in the urine in a given time interval was divided by the total dose given and multiplied by 100 to obtain the percentage of dose excreted in that interval. To calculate renal clearance (CL R ), the amount of drug excreted in the urine over a 24 h period was divided by AUCpo, and was compared to GFR•f u , to assess if net active renal transport was present (if CL R > GFR•f u , net renal secretion is suggested; if CL R < GFR•f u , net renal absorption is suggested). GFR values for the different species were obtained from the literature (Davies and Morris, 1993) .
For the analysis of clinical samples, the slopes of the terminal phases of the plasma dapagliflozin, and plasma TRA concentration-time profiles, λ, was determined by logThis article has not been copyedited and formatted. The final version may differ from this version. linear regression of at least three data points which yielded a minimum mean square error.
The absolute values of λ were used to estimate the apparent terminal half-lives of plasma dapagliflozin and plasma TRA by: t 1/2 = 2/λ. The areas under the plasma dapagliflozin and TRA concentration-time curves from zero extrapolated to infinite time, AUCtot, were calculated by log-and linear-trapezoidal summations over the collection time, with the last quantifiable plasma concentration being divided by λ and the product added to the total area. The total apparent (oral) body clearance was calculated using CL/F = Dose/AUC.
The calculated half-life is after an oral dose.
For the clinical urine samples, the percent of total radioactivity excreted in the urine was calculated as described above, based on the total radioactive dose. For dapagliflozin excretion, chromatographic separation of the dapagliflozin and scintillation counting was described in the above sections, and percentage of dose excreted was calculated as described above.
Prediction of CL and CL/F in humans.
Allometric scaling was used to estimate the human clearance of dapagliflozin by using the body weight of the animal and the corresponding clearance values. The animal clearance values after correction for interspecies differences in plasma protein binding (not shown) were also used and that predicted clearance compared to the value from simple allometry. In order to compare the predicted clearance from allometry to the apparent clearance after an oral dose, the predicted clearance was divided by the average oral bioavailability of the animal species (64%).
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Caco-2 permeability and P-gp interactions. The permeability coefficient (Pc) of dapagliflozin in the apical to basolateral direction was 60 nm/sec at an initial concentration of 50 µM at pH 7.4. This value is comparable to compounds that exhibit moderate absorption in humans (Marino et al., 2005) . Under the same conditions, the average B-to-A Pc value of dapagliflozin was 227 nm/sec (BA/AB ratio of 3.8). In the presence of a Pgp inhibitor, the A-to-B permeability of dapagliflozin was 159 nm/sec and the B-to-A permeability was 188 nm/sec (BA/AB ratio decreased to 1.2). The BA/AB ratio of 3.8 and the decrease of P-gp mediated efflux (in the presence of a P-gp inhibitor) suggests that dapagliflozin may be a P-gp substrate.
To evaluate whether dapagliflozin inhibits the transport of P-gp substrates, the permeability of digoxin was measured across Caco-2 cell monolayers in the presence and absence of dapagliflozin at 10 μM. Dapagliflozin showed weak inhibition of digoxin transport (10% at 10 μM). The inhibition value for verapamil (a known P-gp inhibitor) was 65% at 10 μM in this experiment. These results suggest the dapagliflozin is unlikely to be a P-gp inhibitor.
Plasma and serum protein binding. The plasma protein binding of dapagliflozin was
determined by the equilibrium dialysis technique at 10 μM and was found to be 95%, 93%, and 91% in rat, dog, and human, respectively. The serum protein binding of dapagliflozin in cynomolgus monkeys was determined by the ultrafiltration technique at 10 μM and was found to be 91%. Control studies established that dapagliflozin was stable in rat, dog, monkey and human serum at 10 μM for 4 hours at 37°C. 
Metabolite profiles from hepatocyte incubations.
Metabolite profiles of [ 14 C]dapagliflozin after incubation for 3 h with hepatocyte preparations from mouse, rat, dog, monkey, and human are shown in Figure 1 . Dapagliflozin was the major peak in all hepatocyte incubations. The extent of turnover of dapagliflozin in hepatocytes was 50% in rat, 26% in mouse, 24% in dog, 25% in monkey, and 10% in human. All metabolites observed in human hepatocyte incubations were also observed in the animal incubations.
In human hepatocytes, M15 was the major metabolite, accounting for 2.1% of the total This article has not been copyedited and formatted. The final version may differ from this version. Metabolites formed in incubations with hepatocytes were characterized by LC/MS/MS.
The mass spectra of dapagliflozin and metabolites M8, M12, and M15 are shown in Figure   2 . The evidence for the assignment of the structure of each metabolite is discussed below. . From its mass spectra, the cleavage of the sugar ring to form an m/z of 289 confirms that the oxidation could only occur on the hydroxymethyl group of the sugar ring. Thus M16 was tentatively identified as an oxidative metabolite of dapagliflozin. This peak was not adequately separated from dapagliflozin to allow quantification, however it was judged to be very minor in separate analysis of select samples with radioflow detection.
Dapagliflozin gave an ammonia adduct (M+NH
Pharmacokinetics and bioavailability of dapagliflozin after single doses in rats, dogs, and monkeys. The main pharmacokinetic parameters for dapagliflozin for all species tested are summarized in Table 1 and the plasma profiles are shown in Figure 4 . The clearance values reported in Table 1 are plasma clearance values, which below are corrected for blood to plasma ratios, for comparison to liver blood flows.
In the rat, the systemic blood clearance of dapagliflozin was 6.8 ± 0.8 mL/min/kg, which is ~ 12 % of hepatic blood flow. The blood clearance was calculated by dividing the plasma clearance by the blood to plasma ratio; for rat those values were 4.8 mL/min/kg, and a ratio 0.7 L/kg for total body water in the rat, indicating extravascular distribution. The estimated elimination half-life after IA administration was 4.6 ± 0.8 h and the mean residence time was 5.6 ± 0.9 h. The oral bioavailability of dapagliflozin was 84%. The time to reach peak concentrations (Tmax) after an oral dose was 1.7 ± 2.0 h.
In the dog, the systemic blood clearance of dapagliflozin was 2.5 ± 0.3 mL/min/kg, which is ~ 8 % of hepatic blood flow in the dog. The steady state volume of distribution was 0.8 ± 0.1 L/kg, similar to total body water in the dog (0.6 L/kg), indicating modest extravascular distribution. The estimated elimination half-life after IV administration was 7.4 ± 1.2 h and the mean residence time was 9.3 ± 0.7 h. The oral bioavailability of dapagliflozin was 83 ± 2%. The Tmax after an oral dose was 0.6 ± 0.4 h. The percent of dose excreted in the urine as dapagliflozin, over a 24 hour period, was 3.4 ± 0.2 % after an oral dose of 6.6 mg/kg.
The CL R was 0.7 mL/min, and GFR*fu was 4.3 mL/min.
In the monkey, dapagliflozin was cleared more quickly than in the dog, with a systemic blood clearance of 8.8 ± 3.1 mL/min/kg , about 20 % of hepatic blood flow in the monkey.
The steady state volume of distribution was 0.8 ± 0.2 L/kg, similar to total body water (0.7 L/kg), indicating modest extravascular distribution. The estimated elimination half-life was after IV administration was 3.5 ± 1.9 h and the mean residence time was 2.2 ± 0.5 h. The oral bioavailability of dapagliflozin was 25 ± 2 %. The Tmax after an oral dose was 1.9 ± 1.8 h. The percent of dose excreted in the urine as dapagliflozin, over a 24 hour period was 3.8 ± 0.3% after an oral dose of 6 mg/kg. The CL R was 5.7 mL/min, and GFR*fu was 0.9 mL/min.
This article has not been copyedited and formatted. The final version may differ from this version. Prediction of pharmacokinetics in humans. The human systemic plasma clearance was predicted to be 2.1 mL/min/kg from simple allometry (CL = 4.26*BW 0.83 , R 2 = 0.87, Figure 5 ). Utilizing the blood to plasma ratio of 0.88 in human serum, this is a blood clearance of 2.4 mL/min/kg, corresponding to 11% of hepatic blood flow. The plasma clearance, when divided by the average bioavailability across the animal species (64%), corresponds to a predicted oral clearance of 3.3 mL/min/kg. The systemic plasma clearance value after correction for protein binding was 1.9 mL/min/kg (oral clearance of 3.0 mL/min/kg). Correction of the plasma clearance with metabolism rates was not done,
given the interspecies differences in metabolite profiles in hepatocytes.
Pharmacokinetics of dapagliflozin after a single dose to humans. Dapagliflozin was rapidly absorbed after oral administration of the 50 mg dose with maximum plasma concentrations (Cmax) attained within 1 hour after administration in a fasted state (Table   1 ). The mean terminal half-life (T1/2) value for dapagliflozin was 13.8 h. The observed oral plasma clearance was 4.9 mL/min/kg. The amount of total radioactivity recovered in the urine was 75.2%; the amount of unchanged dapagliflozin recovered in urine was 1.6%.
The CL R was 5.6 mL/min and GFR•f u was 10.8 mL/min. Figure 6 shows the plasma profile of dapagliflozin compared to plasma profile of total radioactivity. The levels of total radioactivity were approximately 3-fold higher than the levels of dapagliflozin. Five timepoints, at 1, 4, 12, 48, and 144 h were sampled for biotransformation analysis. Dapagliflozin and M15 levels were quantitated as described in the methods section. Timepoints after 96 h were below the lower limit of quantitation (BQL) for dapagliflozin. The total radioactivity measurements were BQL after 24 hr. In order to aid in compound selection and to determine whether dapagliflozin was a suitable compound for progression into the clinic, the pharmacokinetics in animals and important ADME parameters were obtained. The plasma clearance of dapagliflozin was low in the three species investigated. The volume of distribution values ranged from total body water in the dog and monkey to about 2-fold total body water in the rat. The elimination half lives were moderate in the rat (4.6 h) and dog (7.4 h) but lower in the monkey (3.5 h). The plasma and serum (monkey) protein binding for dapagliflozin was found to be moderate to high, ranging from 91% to 95% in preclinical species, and 91% in humans. Bioavailability values ranged from >80% in the rat and dog to 25% in the monkey. The predicted oral clearance using the clearance values from simple allometry was 3.3 mL/min/kg, based on an average bioavailability value calculated from the different species.
The intrinsic permeability seen for dapagliflozin across Caco-2 cells was comparable to compounds that exhibit good absorption in humans (Marino et al., 2005) , and would DMD 29165
-32 -indicate good systemic bioavailability of the compound after oral administration. The efflux ratio of 3.8 seen in Caco-2 cells suggests that dapagliflozin may be a P-gp substrate, but it exhibits high intrinsic permeability in the Caco-2 cells and good bioavailability in rats and dogs, and thus absorption and bioavailability were predicted to be adequate in humans. It is possible that the doses in rats and dogs were enough to saturate the P-gp transporter at the level of the intestinal lumen and lead to the observed good bioavailability, however, dapagliflozin demonstrated linear pharmacokinetics over a very large dose range in both species so it is more likely that passive permeability dominates the absorption of the compound. P-gp can play a role in drug disposition at the level of the kidney (Li et al., 2006) . While the comparison of GFR•fu to CL R for monkeys and dogs does indicate that some active renal processes may be occurring, it should be noted that the urinary excretion of dapaglifozin is very low in all species, so the action of P-gp on the disposition of dapagliflozin at the renal level may not be relevant. And while the bioavailability in the monkey is much lower than in other species, factors other than renal transport are governing the lower oral exposure.
In incubations with human hepatocytes, a glucuronide conjugate (M15) of dapagliflozin was found to be the major metabolite. Glucuronides of dapagliflozin (M15 and M10) were also found in the animal hepatocyte incubations. Dapagliflozin was not found to be an inhibitor or an inducer of CYP enzymes. The overall favorable ADME properties of dapagliflozin in animals, the favorable predicted parameters in humans, and the overall safety and efficacy of the compound in preclinical testing led to the progression of the compound into clinical trials (List et al.,2008; ; ).
This article has not been copyedited and formatted. The final version may differ from this version. Dapagliflozin, administered to healthy subjects as an oral solution of 50 mg, was rapidly absorbed from the gastrointestinal tract with Tmax < 1 h, and appeared to be safe and welltolerated. Based on the urinary recovery of total radioactivity in that study, the systemic absorption of orally administered dapagliflozin was at least 75% within 24 h of dosing (data not shown). Thus P-gp does not appear to be limiting the absorption of dapagliflozin in humans. The urinary excretion of (parent) dapagliflozin is very low, thus the contribution of renal clearance to the total clearance of dapagliflozin is very small.
In plasma, the ratio of the dapagliflozin concentration to the TRA at any one time point was approximately 0.3 of TRA, suggesting that metabolites account for a significant portion of dapagliflozin-related compounds in the plasma. Indeed, the major metabolite identified in human hepatocytes was also found to be a major circulating metabolite in the clinical samples. This non-pharmacologically active glucuronide conjugate, M15 (further characterization to be discussed in a future publication), was found in human plasma at concentrations similar to dapagliflozin. M15 was cleared similarly to dapagliflozin as indicated by the comparable slopes of their elimination phases. Levels of M15 were significant in all species used for toxicological evaluation (data not shown) relative to levels in humans.
Allometry rather than in vitro data was used to predict human clearance for a number of reasons. Clearance predictions from microsomal incubations with NADPH, accounting for only oxidative metabolism, or from microsomal incubations with UDPGA were not done as the predicted clearance values often underpredict observed values for drugs cleared by glucuronidation and are highly dependent on incubation conditions (Kilford, et al., 2009 cleared by glucuronidation, the preclinical studies with hepatocytes did not give enough dapagliflozin turnover to reliably determine an intrinsic clearance. Thus, allometry was used as a reasonable alternative. The oral clearance (3.3 mL/min/kg) predicted from simple allometry is quite close to the observed value (4.9 mL/min/kg); correcting for protein binding resulted in a very similar prediction of oral clearance (3.0 mL/min/kg).
Dapagliflozin is a low clearance compound in humans.
In summary, dapagliflozin is a potent inhibitor of SGLT2, and shows a reduction in plasma glucose in animal models Meng et al., 2008) . b Urinary excretion of dapagliflozin (after an oral dose) in dogs was 3.4 ± 0.2%; in monkeys was 3.8 ± 0.3%, and in humans was 1.6 ± 0.8 % of the total dose. Urinary excretion was not measured in rats.
c CL/F (observed).
d Vss, F were not calculated in humans, as there was not IV data.
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